3087-14-7

Basic information

• Product Name: 2-(methylsulfanyl)-1,5,6,7-tetrahydro-4H-cyclopenta[d]pyrimidin-4-one
• Synonyms: 2-(Methylsulfanyl)-3,5,6,7-tetrahydro-4H-cyclopenta[d]pyrimidin-4-one; 4H-cyclopenta[d]pyrimidin-4-one, 3,5,6,7-tetrahydro-2-(methylthio)-
• CAS NO: 3087-14-7
• Molecular Formula: C₈H₁₀N₂OS
• Molecular Weight: 182.2428
• Mol File: 3087-14-7.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 326.9°C at 760 mmHg
• Flash Point: 151.5°C
• Density: 1.46g/cm³
• Vapor Pressure: 0.00021mmHg at 25°C
• Refractive Index: 1.714
• CAS DataBase Reference: 2-(methylsulfanyl)-1,5,6,7-tetrahydro-4H-cyclopenta[d]pyrimidin-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(methylsulfanyl)-1,5,6,7-tetrahydro-4H-cyclopenta[d]pyrimidin-4-one(3087-14-7)
• EPA Substance Registry System: 2-(methylsulfanyl)-1,5,6,7-tetrahydro-4H-cyclopenta[d]pyrimidin-4-one(3087-14-7)

Safety Data

• Hazardous Substances Data: 3087-14-7(Hazardous Substances Data)

Usage

Bicyclic heterocyclic compound

Derived from cyclopenta[d]pyrimidin-4-one

Sulfur-containing compound

Has a methylsulfanyl group attached to the ring
Belongs to the class of organic compounds known as pyrimidines
Used in organic synthesis and medicinal chemistry
Potential applications in pharmaceuticals and therapeutic agent development due to unique structural and chemical properties.

Upstream product

• 35563-27-0 2-sulfanylidene-1,2,3,4,6,7-hexahydro-5H-cyclopenta[d]pyrimidin-4-one 
• 74-88-4 methyl iodide 
• 77766-02-0 4-amino-2-methylthio-5,6-trimethylenepyrimidine 
• 120-92-3 cyclopentanone 
• 611-10-9 2-ethoxycarbonyl-1-cyclopentanone 
• 2986-19-8 carbamimidothioic acid methyl ester 
• 14527-26-5 2-methylisothiourea sulphate 
• 10472-24-9 methyl 2-oxocyclopentane-1-carboxylate 
• 147895-43-0 S-methylisothiourea hemisulphate 

Downstream Products

• 33017-96-8 2-morpholin-4-yl-3,5,6,7-tetrahydro-cyclopentapyrimidin-4-one 
• 51660-15-2 4-chloro-2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidine 
• 5466-00-2 6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diol 
• 5466-43-3 2,4-dichloro-6,7-dihydro-5H-cyclopentapyrimidine 
• 5466-00-2 1,5,6,7-tetrahydro-cyclopentapyrimidine-2,4-dione 
• 7511-98-0 2-methylsulfanyl-3,5,6,7-tetrahydro-cyclopentapyrimidine-4-thione 
• 791734-57-1 2-(4-benzyl-1-piperazinyl)-4-methylamino-5,6-trimethylenepyrimidine 
• 78043-15-9 2-(4-benzyl-1-piperazinyl)-4-chloro-5,6-trimethylenepyrimidine 
• 79051-07-3 2-(4-benzyl-1-piperazinyl)-5,6-trimethylene-4(3H)-pyrimidinone 
• 4344-74-5 1,2,3,4,5,6-hexahydro-cyclopentapyrazol-3-on 
• 905086-67-1 2-(4-chloro-anilino)-3,5,6,7-tetrahydro-cyclopentapyrimidin-4-one 

Relevant articles and documents

Synthetic method of medical intermediate cycloalkanopyrimidinedione compound

The invention provides a synthetic method of a cycloalkanopyrimidinedione compound, and belongs to the technical field of organic synthesis. The method provided by the invention comprises the following steps of: taking a 2-methoxycarbonyl naphthenone comp

BICYCLIC DERIVATIVE CONTAINING PYRIMIDINE RING, AND PREPARATION METHOD THEREFOR

The present invention provides: a bicyclic derivative comprising a pyrimidine ring, or a pharmaceutically acceptable salt thereof; a preparation method therefor, a pharmaceutical composition comprising the same; and a use therefor. According to the present invention, the bicyclic compound derivative comprising a pyrimidine ring, or a pharmaceutically acceptable salt thereof acts as a 5-HT4 receptor agonist, and thus can be usefully applied to the prevention or treatment of dysfunction in gastrointestinal motility, for example, gastrointestinal diseases such as gastroesophageal reflux disease (GERD), constipation, irritable bowel syndrome (IBS), dyspepsia, post-operative ileus, delayed gastric emptying, gastroparesis, intestinal pseudo-obstruction, drug-induced delayed transit, diabetic gastric atony and the like.

Carboxylic acid derivatives, their preparation and use in treating cancer

This invention provides a method for treating cancer in an individual, wherein the cancer is a tumor in which endothelin is upregulated (e.g. tumors of the prostate, lung, liver, breast, brain, stomach, colon, endometrium, testicle, thyroid, pituatary, bladder, kidney, pancreas and meninges) by administering to the individual an effective amount of a compound of Formula I or Formula Ia, as describe herein.